Cancer Stem Cells in Soft-Tissue Sarcomas
Authors:
- Paula Martínez-DelgadoPMPaula Martínez-Delgado
- Serena LacerenzaSLSerena Lacerenza
- Antonia Obrador-HeviaAOAntonia Obrador-Hevia
- Maria Lopez-AlvarezMLMaria Lopez-Alvarez
- José L. Mondaza-HernandezJMJosé L. Mondaza-Hernandez
- Elena Blanco-AlcainaEBElena Blanco-Alcaina
- Paloma Sanchez-BustosPSPaloma Sanchez-Bustos
- Nadia HindiNadia Hindi
- David S. MouraDMDavid S. Moura
- Javier Martin-BrotoJavier Martin-Broto
Open Access
Abstract
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic profiles and clinical features. Systemic chemotherapy is the backbone treatment for advanced STS; however, STS frequently acquire resistance to standard therapies, which highlights the need to improve treatments and identify novel therapeutic targets. Increases in the knowledge of the molecular pathways that drive sarcomas have brought to light different molecular alterations that cause tumor initiation and progression. These findings have triggered a breakthrough of targeted therapies that are being assessed in clinical trials. Cancer stem cells (CSCs) exhibit mesenchymal stem cell (MSC) features and represent a subpopulation of tumor cells that play an important role in tumor progression, chemotherapy resistance, recurrence and metastasis. In fact, CSCs phenotypes have been identified in sarcomas, allied to drug resistance and tumorigenesis. Herein, we will review the published evidence of CSCs in STS, discussing the molecular characteristic of CSCs, the commonly used isolation techniques and the new possibilities of targeting CSCs as a way to improve STS treatment and consequently patient outcome.Keywords
This publication has 137 references indexed in Scilit:
- Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)Journal of Translational Medicine, 2012
- CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSVPediatric Blood & Cancer, 2012
- High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/β-Catenin Target Gene, CDC25ACancer Cell, 2011
- A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomasCancer, 2011
- Evidence for an Unanticipated Relationship between Undifferentiated Pleomorphic Sarcoma and Embryonal RhabdomyosarcomaCancer Cell, 2011
- Integrated Proteomics and Genomics Analysis Reveals a Novel Mesenchymal to Epithelial Reverting Transition in Leiomyosarcoma through Regulation of SlugMolecular & Cellular Proteomics, 2010
- EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cellsGenes & Development, 2010
- Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathwayJournal of Clinical Investigation, 2007
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ‐C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)Sarcoma, 2005